30093-97-1

Basic information

• Product Name: 4,5-dihydro-3,4,4-trimethyloxazolium iodide
• Synonyms: 4,5-dihydro-3,4,4-trimethyloxazolium iodide;Einecs 250-044-1
• CAS NO: 30093-97-1
• Molecular Formula: C₆H₁₂NO*I
• Molecular Weight: 241.07005
• EINECS: 250-044-1
• Mol File: 30093-97-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(30093-97-1)
• EPA Substance Registry System: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(30093-97-1)

Safety Data

• Hazardous Substances Data: 30093-97-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H12NO.HI/c1-6(2)4-8-5-7(6)3;/h5H,4H2,1-3H3;1H/q+1;/p-1

Upstream product

• 30093-99-3 4,4-dimethyl-2-oxazoline 
• 74-88-4 methyl iodide 
• 504-77-8 4,5-dihydro-1,3-oxazol 

Downstream Products

• 184955-24-6 1-Phenyl-2-(3,4,4-trimethyl-oxazolidin-2-yl)-ethanone 
• 182363-00-4 (Z)-3-[(2-Hydroxy-1,1-dimethyl-ethyl)-methyl-amino]-1-phenyl-propenone 
• 95-16-9 1,3-Benzothiazole 
• 2843-27-8 N-(2-hydroxyphenyl)formamide 
• 51-17-2 benzoimidazole 
• 491-36-1 4-Hydroxyquinazoline 
• 3179-31-5 3-mercapto-1,2,4-triazole 
• 3179-31-5 1H-[1,2,4]triazole-3-thiol 

Relevant articles and documents

Pictet-Spengler reaction: Is carbonyl the best choice? A highly diastereoselective alternative approach to trans-1,3-disubstituted tetrahydro-β-carbolines

Unprecedented 1,2,3-trisubstituted tetrahydro-β-carbolines (THBCs) have been synthesized via a short and highly diastereoselective synthetic route. The key step of the sequence is a flexible variant of the Pictet-Spengler reaction employing synthetic equivalents of several non-available carbonyl compounds. Using one such synthon, the resultant THBC could be further ring- closed to a tetracyclic indole alkaloidal skeleton. (C) 2000 Elsevier Science Ltd.

Leukotriene antagonists

Leukotriene antagonist thiadiazoles have been prepared.

ESTER PRODRUGS

This invention relates to ester prodrugs for alkanoic acid compounds useful as leukotriene antagonists, and pharmaceutical compositions containing such ester prodrug compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.